Patents Assigned to Bioregen Biomedical (Changzhou) Co., Ltd.
  • Publication number: 20220273851
    Abstract: A disulfide cross-linked hyaluronic acid gelatin for postoperative abdominal (pelvic) adhesion prevention and a preparation method therefor, wherein the content of disulfide cross-linked hyaluronic acid of the disulfide cross-linked hyaluronic acid gelatin is among 3-8 mg/mL. The disulfide cross-linked hyaluronic acid gelatin not only has favorable biocompatibility, but also has favorable prevention effects on tissue adhesions when being used for postoperative abdominal (pelvic) adhesion prevention.
    Type: Application
    Filed: March 31, 2020
    Publication date: September 1, 2022
    Applicant: BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD.
    Inventors: Yunyun WANG, Hongchen ZHANG, Kun WANG, Mulan HU, Xinyu WANG, Wenjun SONG, Xiaozheng SHU
  • Publication number: 20220105020
    Abstract: A hyaluronic acid skin care composition includes a thiolated hyaluronic acid derivative; and a hyaluronic acid or salt of at least one molecular weight of thereof. The composition not only has multiple skin protection effects of the hyaluronic acid itself, but also has strong anti-oxidation ability, and can effectively scavenge reactive oxygen species for skin care.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 7, 2022
    Applicant: BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD.
    Inventors: Yunyun WANG, Xinyu WANG, Wenjun SONG, Hongchen ZHANG, Kun WANG, Xiaozheng SHU
  • Patent number: 10064889
    Abstract: The present invention discloses a mercapto-modified biocompatible macromolecule derivative with a low degree of modification. The mercapto-modified biocompatible macromolecule derivative not only maintains the initial structure, physiological function and biocompatibility as much as possible, but also allows the preparation of the biocompatible macromolecule cross-linked material with a low degree of cross-linking through the effectively chemical cross-linking with the introduced mercapto group. The present invention further discloses a disulfide-bond cross-linked biocompatible macromolecule material with a very low degree of cross-linking.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: September 4, 2018
    Assignee: Bioregen Biomedical (Changzhou) Co., Ltd.
    Inventors: Xiaozheng Shu, Weiping Zhong, Yunyun Wang, Meixia Yu
  • Patent number: 9446067
    Abstract: The present invention discloses a mercapto-modified biocompatible macromolecule derivative with a low degree of modification. The mercapto-modified biocompatible macromolecule derivative not only maintains the initial structure, physiological function and biocompatibility as much as possible, but also allows the preparation of the biocompatible macromolecule cross-linked material with a low degree of cross-linking through the effectively chemical cross-linking with the introduced mercapto group. The present invention further discloses a disulfide-bond cross-linked biocompatible macromolecule material with a very low degree of cross-linking.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: September 20, 2016
    Assignee: Bioregen Biomedical (Changzhou) Co. Ltd.
    Inventors: Xiaozheng Shu, Weiping Zhong, Yunyun Wang, Meixia Yu
  • Publication number: 20160263147
    Abstract: The present invention discloses a mercapto-modified biocompatible macromolecule derivative with a low degree of modification. The mercapto-modified biocompatible macromolecule derivative not only maintains the initial structure, physiological function and biocompatibility as much as possible, but also allows the preparation of the biocompatible macromolecule cross-linked material with a low degree of cross-linking through the effectively chemical cross-linking with the introduced mercapto group. The present invention further discloses a disulfide-bond cross-linked biocompatible macromolecule material with a very low degree of cross-linking.
    Type: Application
    Filed: March 23, 2016
    Publication date: September 15, 2016
    Applicant: Bioregen Biomedical (Changzhou) Co., Ltd.
    Inventors: Xiaozheng SHU, Weiping ZHONG, Yunyun WANG, Meixia YU
  • Patent number: 9220676
    Abstract: The present invention discloses an injectable in-situ crosslinked hydrogel and its preparation method. The preparation method is as below: Filling the crosslinking active solution of at least one kind of the biocompatible macromolecules containing more than two thiol groups on the side chains into an injectable container and sealing it, and forming the in-situ disulfide-bond crosslinked hydrogel under the action of the dissolved oxygen; through controlling such parameters as partial pressure of oxygen gas, temperature and time, regulating concentration of the oxygen dissolved in the crosslinking active solution, and optimizing the gelation process and the gel properties. The present invention further relates to application of the injectable in-situ crosslinked hydrogel in pharmaceutics or surgery.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: December 29, 2015
    Assignee: Bioregen Biomedical (Changzhou) Co., Ltd.
    Inventor: Xiaozheng Shu
  • Patent number: 8647670
    Abstract: This invention discloses a preparation method for biocompatible rapid-gelating hydrogel. Wherein, hydrogel is formed by rapid chemical-crosslinking using the mixing and chemical-crosslinking reaction under specified conditions between several active compound components. The preparation method comprises the following steps: (1) The solution containing biocompatible thiolated macromolecular derivatives (component A) and biocompatible thiol reactive crosslinking agents (component B) mutually mix to form reactive mixture with specified crosslinking conditions; (2) the reactive mixture forms the hydrogel. The invention also discloses a preparation method for novel rapid-gelating hydrogel spray and an application in medical field. This invention has the advantages of good biocompatibility, no by-products, good stability, convenient use, small amount of raw materials used, suitable for many medical application, etc.
    Type: Grant
    Filed: June 10, 2008
    Date of Patent: February 11, 2014
    Assignee: Bioregen Biomedical (Changzhou) Co., Ltd.
    Inventor: Xiaozheng Shu
  • Publication number: 20130338099
    Abstract: The present invention discloses a mercapto-modified biocompatible macromolecule derivative with a low degree of modification. The mercapto-modified biocompatible macromolecule derivative not only maintains the initial structure, physiological function and biocompatibility as much as possible, but also allows the preparation of the biocompatible macromolecule cross-linked material with a low degree of cross-linking through the effectively chemical cross-linking with the introduced mercapto group. The present invention further discloses a disulfide-bond cross-linked biocompatible macromolecule material with a very low degree of cross-linking.
    Type: Application
    Filed: August 4, 2011
    Publication date: December 19, 2013
    Applicant: BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD.
    Inventors: Xiaozheng Shu, Weiping Zhong, Yunyun Wang, Meixia Yu
  • Patent number: 8158754
    Abstract: Disclosed is a kind of multiple modified derivatives of gelatin having not only the structure of formula (I) but also one of structures of formula (II), (III), and (IV) as well, wherein, G refers to gelatin residue, which can be type A, type B or a gelatin obtained from gene recombination; R1 refers to alkylene, or a linkage group with amide; R2 refers to alkyl, or aryl; R3 refers to alkylene; and R4 refers to carboxyl or carboxylate. The multiple modifying ways of gelatin comprise the hydrophobic modification on the amino group of gelatin through amide bond, carboxylation on the amino group of gelatin through amide bond, thiolation on the carboxyl group of gelatin, and thiolation following carboxylation on amino group of gelatin through amide bond. Also disclosed is a crosslinked material made of multiple modified derivatives of gelatin. The multiple modified derivatives of gelatin have flexible chemical structures and many properties.
    Type: Grant
    Filed: September 29, 2007
    Date of Patent: April 17, 2012
    Assignee: Bioregen Biomedical (Changzhou) Co., Ltd.
    Inventor: Chan Song
  • Patent number: 8124757
    Abstract: The disclosed is thiol-modified macromolecule derivatives having the general formula of (I) or (II), as well as the disulfide bond cross-linked materials and the thiol-reactive crosslinker cross-linked materials, wherein R1 and R2 are alkylene groups, substituted alkylene groups, aromatic groups or polyether groups and the like, respectively. R1 and R2 may have same or different chemical structure, and P is a residue of a macromolecule with side carboxyl group. The thiol-modified macromolecule derivative has a molecular weight of from 1000 to 5,000,000. The thiol-modified macromolecule derivative having the general formula of (I) or (II) of the present invention has a side chain with flexible chemical structure and adjustable properties, and has a number of advantages, such as mild reaction condition, high production yield, high degree of modifying, and the controllable modifying degree and so on.
    Type: Grant
    Filed: September 29, 2007
    Date of Patent: February 28, 2012
    Assignee: Bioregen Biomedical (Changzhou) Co., Ltd.
    Inventor: Chan Song
  • Publication number: 20120034271
    Abstract: The present invention discloses an injectable in-situ crosslinked hydrogel and its preparation method. The preparation method is as below: Filling the crosslinking active solution of at least one kind of the biocompatible macromolecules containing more than two thiol groups on the side chains into an injectable container and sealing it, and forming the in-situ disulfide-bond crosslinked hydrogel under the action of the dissolved oxygen; through controlling such parameters as partial pressure of oxygen gas, temperature and time, regulating concentration of the oxygen dissolved in the crosslinking active solution, and optimizing the gelation process and the gel properties. The present invention further relates to application of the injectable in-situ crosslinked hydrogel in pharmaceutics or surgery.
    Type: Application
    Filed: September 8, 2009
    Publication date: February 9, 2012
    Applicant: BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD
    Inventor: Xiaozheng Shu
  • Publication number: 20100152423
    Abstract: The disclosed is thiol-modified macromolecule derivatives having the general formula of (I) or (II), as well as the disulfide bond cross-linked materials and the thiol-reactive crosslinker cross-linked materials, wherein R1 and R2 are alkylene groups, substituted alkylene groups, aromatic groups or polyether groups and the like, respectively. R1 and R2 may have same or different chemical structure, and P is a residue of a macromolecule with side carboxyl group. The thiol-modified macromolecule derivative has a molecular weight of from 1000 to 5,000,000. The thiol-modified macromolecule derivative having the general formula of (I) or (II) of the present invention has a side chain with flexible chemical structure and adjustable properties, and has a number of advantages, such as mild reaction condition, high production yield, high degree of modifying, and the controllable modifying degree and so on.
    Type: Application
    Filed: September 29, 2007
    Publication date: June 17, 2010
    Applicant: Bioregen Biomedical (Changzhou) Co., Ltd.
    Inventor: Chan Song
  • Publication number: 20100144902
    Abstract: This invention discloses a preparation method for biocompatible rapid-gelating hydrogel. Wherein, hydrogel is formed by rapid chemical-crosslinking using the mixing and chemical-crosslinking reaction under specified conditions between several active compound components. The preparation method comprises the following steps: (1) The solution containing biocompatible thiolated macromolecular derivatives (component A) and biocompatible thiol reactive crosslinking agents (component B) mutually mix to form reactive mixture with specified crosslinking conditions; (2) the reactive mixture forms the hydrogel. The invention also discloses a preparation method for novel rapid-gelating hydrogel spray and an application in medical field. This invention has the advantages of good biocompatibility, no by-products, good stability, convenient use, small amount of raw materials used, suitable for many medical application, etc.
    Type: Application
    Filed: June 10, 2008
    Publication date: June 10, 2010
    Applicant: Bioregen Biomedical (Changzhou) Co., Ltd.
    Inventor: Xiaozheng Shu